恒瑞医药：SHR-1049 注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for the clinical trial of SHR-1049 injection, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Drug Development - SHR-1049 injection is a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-1049 injection project is approximately 26 million yuan (unaudited) [1]